Home / Business and Economy / Baxter Raises Profit Forecast on Strong IV Sales
Baxter Raises Profit Forecast on Strong IV Sales
30 Jul
Summary
- Baxter raised its annual profit forecast due to strong IV solution sales.
- The company beat quarterly estimates, reporting $2.96 billion in revenue.
- Baxter now expects 2026 adjusted profit per share between $1.95 and $2.15.
Baxter International, a medical products manufacturer, has elevated its annual profit projection following a strong sales performance, particularly in its IV solutions segment. The company surpassed financial expectations for the recent quarter.
Baxter reported second-quarter revenue reaching $2.96 billion, exceeding analyst predictions. Sales in its primary medical products and therapies division, which encompasses IV solutions, saw a 7% increase year-over-year, amounting to $2.08 billion.
The company's outlook for 2026 has been revised upward, with adjusted profit per share now anticipated to range from $1.95 to $2.15, an increase from the previous forecast. This financial improvement is occurring as Baxter undertakes a strategic turnaround, focusing on cost-cutting measures.
